New board appointment at Orexigen
This article was originally published in Scrip
Orexigen Therapeutics, a US biopharmaceutical company focused on the treatment of obesity, has elected Dr Peter Honig to its board of directors. Dr Honig has more than 20 years' clinical and regulatory policy experience from past roles with Merck & Co and the US FDA. Most recently, he was senior vice-president of worldwide regulatory affairs and product safety at Merck and co-chair of Merck's late development review committee, overseeing the company's late-stage pipeline.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.